These numbers illustrate a continuing public‑health crisis that demands early detection, comprehensive treatment, and sustained support.

Symptoms

OUD is diagnosed based on a pattern of behaviors and physical signs that meet criteria in the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM‑5). The following list includes the 11 possible criteria; the presence of 2 or more within a 12‑month period indicates OUD, with severity classified as mild (2‑3), moderate (4‑5), or severe (6+).

• Craving or strong desire to use opioids – intense mental preoccupation.
• Loss of control – larger amounts or longer periods of use than intended.
• Unsuccessful efforts to cut down – repeated attempts to reduce use that fail.
• Time spent obtaining, using, or recovering – a large portion of daily life is devoted to opioids.
• Social or occupational impairment – neglect of responsibilities at work, school, or home.
• Continued use despite physical or psychological problems – e.g., worsening chronic pain, depression.
• Tolerance – needing markedly higher doses to achieve the same effect.
• Withdrawal syndrome – physical symptoms (nausea, sweating, shaking, anxiety) when opioid use is reduced or stopped.
• Reduced recreational activities – loss of interest in hobbies or relationships.
• Use in physically hazardous situations – e.g., using while driving.
• Legal problems related to use – arrests, fines, or other legal consequences.

Physical signs of opioid intoxication or withdrawal may also appear:

• Intoxication: pinpoint pupils, drowsiness, slurred speech, slowed breathing.
• Withdrawal: yawning, lacrimation, gooseflesh, abdominal cramps, diarrhea, fever, muscle aches.

Causes and Risk Factors

OUD arises from a complex interplay of pharmacologic, genetic, environmental, and psychosocial factors.

Pharmacologic causes

• Potent opioids (e.g., fentanyl, heroin) produce rapid, intense dopamine release in the brain’s reward pathways, reinforcing use.
• Long‑acting formulations (e.g., extended‑release oxycodone) can lead to higher cumulative exposure.

Genetic and biological factors

• Family studies show a heritability estimate of 40‑60% for opioid dependence.
• Variations in genes controlling opioid receptors (OPRM1) and dopamine metabolism (COMT) influence susceptibility.

Psychosocial risk factors

• History of trauma, adverse childhood experiences, or chronic stress.
• Co‑occurring mental health disorders (depression, anxiety, bipolar disorder, PTSD).
• Poor social support, unemployment, or unstable housing.
• Prescription of high‑dose opioids for chronic non‑cancer pain without adequate monitoring.

Environmental contributors

• Easy access to prescription opioids (e.g., leftover pills from a family member).
• Community-level factors: high prevalence of illicit opioids, lack of treatment resources, and stigma.

Diagnosis

Diagnosis is clinical; no single laboratory test confirms OUD, though testing can support assessment.

Clinical interview

• Gather a comprehensive substance‑use history (type, route, dose, frequency, duration).
• Apply DSM‑5 criteria to determine presence and severity.
• Screen for co‑occurring mental health conditions using validated tools (PHQ‑9, GAD‑7, MINI).

Screening instruments

• Opioid Risk Tool (ORT) – predicts risk of opioid misuse in patients being considered for chronic opioid therapy.
• Clinical Opioid Withdrawal Scale (COWS) – quantifies withdrawal severity.
• Drug Abuse Screening Test (DAST‑10) – brief self‑report measure.

Laboratory tests

• Urine or saliva toxicology screens to confirm recent opioid presence.
• Blood tests for liver function (especially in heavy heroin users) and infectious disease screening (HIV, hepatitis B/C).

Imaging and other assessments

• CT/MRI only when complications (e.g., infectious endocarditis, intracranial abscess) are suspected.
• Pregnancy testing for women of child‑bearing age before initiating medication‑assisted treatment (MAT).

Treatment Options

Effective management combines medication‑assisted treatment (MAT), behavioral therapies, and supportive services. Treatment should be individualized, patient‑centered, and, when possible, started as soon as OUD is identified.

Medication‑Assisted Treatment (MAT)

• Buprenorphine (partial µ‑opioid agonist) – FDA‑approved formulations: Suboxone® (buprenorphine/naloxone), Subutex® (buprenorphine alone). Advantages: ceiling effect on respiratory depression, office‑based prescribing (waivered clinicians).
• Methadone (full µ‑opioid agonist) – Dispensed through certified Opioid Treatment Programs (OTPs). Highly regulated but effective for severe OUD.
• Naltrexone (opioid antagonist) – Oral (daily) or extended‑release injectable (Vivitrol®) formulations. Requires complete detoxification before initiation.

Behavioral and psychosocial therapies

• Cognitive‑behavioral therapy (CBT) – helps identify triggers and develop coping skills.
• Contingency management – provides tangible rewards for drug‑free urine screens.
• Motivational interviewing – strengthens intrinsic motivation for change.
• 12‑step or peer‑support groups (e.g., Narcotics Anonymous) – provide community and accountability.

Integrated care approaches

• Co‑location of primary care, mental‑health services, and MAT improves retention.
• Case management for housing, employment, and legal assistance addresses social determinants of health.

Lifestyle modifications & adjunctive measures

• Regular physical activity (reduces cravings and improves mood).
• Mindfulness‑based stress reduction or yoga.
• Nutrition counseling—balanced diet supports recovery and mitigates weight changes linked to MAT.

Living with Opioid Use Disorder

Recovery is a long‑term process. The following practical tips help maintain sobriety and improve quality of life.

• Stick to a medication schedule. Use a pillbox or smartphone reminder; never skip a dose of buprenorphine or methadone.
• Attend counseling regularly. Even when you feel “stable,” ongoing therapy reinforces coping strategies.
• Build a sober support network. Connect with peers in recovery groups and inform close friends or family of your treatment plan.
• Develop an emergency plan. Keep a list of crisis hotlines (e.g., 988 in the U.S.) and the nearest emergency department.
• Monitor for relapse triggers. Stress, pain flare‑ups, or social situations involving opioids require extra vigilance.
• Practice safe storage. Keep any remaining prescription opioids locked away and dispose of unused medication through take‑back programs.
• Stay on top of health screenings. Annual labs for liver function, infectious disease testing, and mental‑health check‑ins are essential.
• Consider medication dose adjustments. Work with your prescriber if cravings intensify or side effects occur.
• Set realistic goals. Celebrate small milestones (e.g., 30 days medication‑adherent) rather than only long‑term outcomes.

Prevention

Preventing OUD involves actions at individual, community, and policy levels.

For patients and families

• Use opioids only as prescribed; discuss non‑opioid pain options with your clinician.
• Secure leftover pills in a locked container; dispose of them properly.
• Educate teens about the risks of non‑medical opioid use.

For healthcare providers

• Employ prescription‑monitoring programs (PDMPs) to detect multiple prescribers.
• Start with the lowest effective opioid dose and limit duration (usually <4 weeks for acute pain).
• Screen all patients for substance‑use risk before initiating opioids (using ORT or similar tools).
• Offer immediate referral to MAT when misuse is identified.

Public‑health and policy measures

• Expand access to MAT through insurance coverage and removal of prior‑authorization barriers.
• Increase availability of naloxone (opioid‑overdose reversal drug) in pharmacies, schools, and community centers.
• Support syringe‑exchange programs and safe‑injection sites to reduce infectious complications.
• Implement educational campaigns targeting prescribers and the general public.

Complications

If left untreated, OUD can lead to severe medical, psychiatric, and social consequences.

• Overdose and death – Respiratory depression is the leading cause of opioid‑related mortality.
• Infectious diseases – HIV, hepatitis B/C, and bacterial infections (e.g., endocarditis, osteomyelitis) from injection use.
• Cardiovascular problems – Arrhythmias, ischemic heart disease related to chronic stress and drug toxicity.
• Gastrointestinal issues – Chronic constipation, bowel obstruction, or opioid‑induced bowel dysfunction.
• Pregnancy complications – Neonatal abstinence syndrome (NAS), premature birth, placental abruption.
• Mental‑health deterioration – Worsening depression, anxiety, suicidal ideation.
• Legal and socioeconomic impact – Arrests, loss of employment, housing instability.

When to Seek Emergency Care

References

1. American Society of Addiction Medicine. Clinical Practice Guidelines for the Use of Medications in Treating Opioid Use Disorder. 2023.
2. Centers for Disease Control and Prevention. Drug Overdose Data. Updated 2024.
3. National Institute on Drug Abuse. Opioid Use Disorder Fact Sheet. 2023.
4. World Health Organization. Guidelines for the Management of Opioid Use Disorder. 2022.
5. Mayo Clinic. Opioid Addiction. Accessed April 2026.
6. Substance Abuse and Mental Health Services Administration. 2023 NSDUH Annual Report.
7. Cleveland Clinic. Opioid Use Disorder. Updated 2024.